Abstract 829P
Background
Follicular lymphoma (FL) is the second most common B-cell non-Hodgkin lymphoma that is defined by unique somatic mutation and gene expression profile. Differences in the genomic profile of FL by age and by sex have not been well characterized.
Methods
We analyzed data from 155 patients with FL who underwent next generation sequencing and RNA expression analysis using the Genomic Testing Cooperative Hematology Plus platform. The DNA and RNA panels assessed 179 genes and 1408 genes, respectively. Our analysis was based on sex (male n=75, female n=80) and age (<50 years, n=20; 50-74 years, n=109; >75 years, n=26). Data and statistics were analyzed with Bioconductor R package Maftools and Broad Institute Gene Set Enrichment Analysis.
Results
At least one somatic mutation in epigenetic genes: KMT2D (n=106), CREBBP (n=98), EZH2 (n=41) and EP300 (n=27) were present in 95% of all patients (n=155). Mutations in B2M were significantly enriched in females (10% vs 1.3%, p=0.035), while mutations in MEF2B were significantly enriched in males (24% vs 10%, p=0.030). Mutations in EP300 were enriched in the young cohort (<50; 35% vs 14%, p=0.047). Mutations in genes: BCR (Breakpoint Chain Region; 23% vs 3.9%, p=0.0033), CREBBP (81% vs 60%, p=0.047), STAT6 (23% vs 8.5%, p=0.042) and TET2 (19% vs 6.2%, p=0.045) were enriched in the elderly cohort (>75). All BCR mutations (missense and truncations), occurred within the N-terminus kinase domain of the gene. These mutations have not been well characterized in FL and are predicted to be deleterious; involving a coiled-coil domain essential for oligomerization and gene function. These mutations may compromise its function as a regulator of RAC1 and RHOA proteins. Correlation with limited available clinical data also suggests that these mutations are seen with aggressive FL or FL undergoing transformation. RNA expression did not show any significant differences based on age or sex.
Conclusions
Our study suggests that there are age and gender specific genomic alterations in FL. We plan to follow up with validation studies in a larger cohort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Genomic Testing Cooperative.
Funding
Has not received any funding.
Disclosure
A. Novak: Other, Personal, Funding, Research funding: Bristol Myers Squibb. M. Albitar: Financial Interests, Personal, Leadership Role, CEO, CMO and own stocks: Genomic Testing cooperative. H. Tun: Financial Interests, Personal and Institutional, Research Grant: Gossamar Bio, Acrotech; Financial Interests, Personal, Advisory Board: Curis. All other authors have declared no conflicts of interest.
Resources from the same session
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18